SG11201501538VA - Glucosylceramide synthase inhibitors - Google Patents
Glucosylceramide synthase inhibitorsInfo
- Publication number
- SG11201501538VA SG11201501538VA SG11201501538VA SG11201501538VA SG11201501538VA SG 11201501538V A SG11201501538V A SG 11201501538VA SG 11201501538V A SG11201501538V A SG 11201501538VA SG 11201501538V A SG11201501538V A SG 11201501538VA SG 11201501538V A SG11201501538V A SG 11201501538VA
- Authority
- SG
- Singapore
- Prior art keywords
- synthase inhibitors
- glucosylceramide synthase
- glucosylceramide
- inhibitors
- synthase
- Prior art date
Links
- 239000003892 ceramide glucosyltransferase inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261699714P | 2012-09-11 | 2012-09-11 | |
PCT/US2013/058896 WO2014043068A1 (fr) | 2012-09-11 | 2013-09-10 | Inhibiteurs de synthase de glucosylcéramide |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201501538VA true SG11201501538VA (en) | 2015-03-30 |
Family
ID=49226563
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201501538VA SG11201501538VA (en) | 2012-09-11 | 2013-09-10 | Glucosylceramide synthase inhibitors |
SG10201701966RA SG10201701966RA (en) | 2012-09-11 | 2013-09-10 | Glucosylceramide synthase inhibitors |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201701966RA SG10201701966RA (en) | 2012-09-11 | 2013-09-10 | Glucosylceramide synthase inhibitors |
Country Status (38)
Country | Link |
---|---|
US (3) | US20150210681A1 (fr) |
EP (2) | EP2895484B1 (fr) |
JP (1) | JP6430943B2 (fr) |
KR (1) | KR102216532B1 (fr) |
CN (3) | CN108864076B (fr) |
AR (1) | AR092522A1 (fr) |
AU (1) | AU2013315715A1 (fr) |
BR (1) | BR112015005227A2 (fr) |
CA (1) | CA2884144C (fr) |
CL (1) | CL2015000529A1 (fr) |
CR (1) | CR20150150A (fr) |
DK (1) | DK2895484T3 (fr) |
DO (1) | DOP2015000039A (fr) |
EA (2) | EA038536B1 (fr) |
ES (1) | ES2911685T3 (fr) |
GT (1) | GT201500051A (fr) |
HK (1) | HK1212681A1 (fr) |
HR (1) | HRP20220310T1 (fr) |
HU (1) | HUE058085T2 (fr) |
IL (1) | IL237355B (fr) |
JO (1) | JOP20130273B1 (fr) |
LT (1) | LT2895484T (fr) |
MA (1) | MA37975B2 (fr) |
MX (2) | MX2020002867A (fr) |
MY (1) | MY186824A (fr) |
NZ (1) | NZ706296A (fr) |
PE (1) | PE20150734A1 (fr) |
PH (1) | PH12015500431A1 (fr) |
PL (1) | PL2895484T3 (fr) |
PT (1) | PT2895484T (fr) |
RS (1) | RS63130B1 (fr) |
SG (2) | SG11201501538VA (fr) |
SI (1) | SI2895484T1 (fr) |
TN (1) | TN2015000091A1 (fr) |
TW (1) | TWI627171B (fr) |
UA (1) | UA118747C2 (fr) |
UY (1) | UY35024A (fr) |
WO (1) | WO2014043068A1 (fr) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA37975B2 (fr) * | 2012-09-11 | 2021-03-31 | Genzyme Corp | Inhibiteurs de synthase de glucosylcéramide |
SG11201506415XA (en) * | 2013-03-15 | 2015-09-29 | Genzyme Corp | Method of preparing glucosylceramide synthase inhibitors |
US20160361301A1 (en) * | 2013-12-11 | 2016-12-15 | Genzyme Corporation | Glucosylceramide synthase inhibitors |
FR3017867A1 (fr) * | 2014-02-21 | 2015-08-28 | Inventiva | Nouveaux composes de type phenylazetidine carboxylate ou carboxamide |
MX2017001648A (es) * | 2014-08-04 | 2017-04-27 | Genzyme Corp | Biomarcadores de enfermedad poliquistica renal y usos de los mismos. |
TW201642855A (zh) * | 2015-03-10 | 2016-12-16 | 健臻公司 | 用於治療蛋白質病變之方法 |
US10471023B2 (en) | 2015-03-12 | 2019-11-12 | British Columbia Cancer Agency Branch | Bisphenol ether derivatives and methods for using the same |
CN108700594B (zh) | 2015-11-18 | 2021-06-29 | 建新公司 | 多囊性肾病的生物标志物及其用途 |
EP3222292A1 (fr) | 2016-03-03 | 2017-09-27 | Heidelberg Pharma GmbH | Conjugués d'amanitine |
US20170298033A1 (en) | 2016-04-15 | 2017-10-19 | The University Of British Columbia | Bisphenol derivatives and their use as androgen receptor activity modulators |
KR20230109185A (ko) | 2016-06-07 | 2023-07-19 | 자코바이오 파마슈티칼스 컴퍼니 리미티드 | Shp2 억제제로서 유용한 신규한 헤테로환형 유도체 |
TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之1H-咪唑並[4,5-b]吡啶-2(3H)-酮及其作為GLUN2B受體調節劑之用途 |
EP3318277A1 (fr) | 2016-11-04 | 2018-05-09 | Institut du Cerveau et de la Moelle Epiniere-ICM | Inhibiteurs de la synthase de glucosylcéramide pour le traitement de maladies du motoneurone |
JP6878615B2 (ja) | 2017-03-23 | 2021-05-26 | ジャコバイオ ファーマスーティカルズ カンパニー リミテッドJacobio Pharmaceuticals Co., Ltd. | Shp2阻害剤として有用な新規な複素環式誘導体 |
CN109111447A (zh) | 2017-06-23 | 2019-01-01 | 中国科学院上海药物研究所 | 7-位取代吡咯并三嗪类化合物或其药学上可用的盐,及其制备方法和用途 |
EP3728265A1 (fr) | 2017-12-21 | 2020-10-28 | BIAL - BioTech Investments, Inc. | Composé de cyclohexyl pyrazolo[1,5-a]pyrimidinyl carboxamide substitué cristallin et ses utilisations thérapeutiques |
US11008302B2 (en) | 2018-04-04 | 2021-05-18 | Janssen Pharmaceutica Nv | Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators |
US11485713B2 (en) | 2018-05-25 | 2022-11-01 | Essa Pharma, Inc. | Androgen receptor modulators and methods for their use |
US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
CN109709202A (zh) * | 2018-12-29 | 2019-05-03 | 辉源生物科技(上海)有限公司 | 一种半乳糖神经酰胺转移酶抑制剂药物的快速筛选方法 |
EP3920912A1 (fr) * | 2019-02-04 | 2021-12-15 | Genzyme Corporation | Traitement de ciliopathies à l'aide d'inhibiteurs de la glucosylcéramide synthase (gcs) |
WO2020198711A1 (fr) * | 2019-03-28 | 2020-10-01 | Essa Pharma, Inc. | Modulateurs du récepteur des androgènes et méthodes associées à utiliser en tant que ligands chimères ciblant la protéolyse |
EP3982958A1 (fr) | 2019-06-14 | 2022-04-20 | Janssen Pharmaceutica NV | Pyrazolo-pyridines hétéroaromatiques substituées et leur utilisation en tant que modulateurs du récepteur glun2b |
MX2021015508A (es) | 2019-06-14 | 2022-01-31 | Janssen Pharmaceutica Nv | Carbamatos de piridina y su uso como moduladores del receptor glun2b. |
JP2022536773A (ja) | 2019-06-14 | 2022-08-18 | ヤンセン ファーマシューティカ エヌ.ベー. | 置換ピラゾロピラジン及びglun2b受容体調節因子としてのそれらの使用 |
US20220324860A1 (en) | 2019-06-14 | 2022-10-13 | Janssen Pharmaceutica Nv | SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS |
CR20210580A (es) | 2019-06-14 | 2022-01-31 | Janssen Pharmaceutica Nv | Amidas depirazol-piridina sustituidos y su uso como moduladores del receptor glun2b |
AU2020290772A1 (en) | 2019-06-14 | 2022-01-06 | Janssen Pharmaceutica Nv | Pyrazine carbamates and their use as GluN2B receptor modulators |
EP4005638A4 (fr) | 2019-07-29 | 2023-07-05 | Takeda Pharmaceutical Company Limited | Composé hétérocyclique |
EP4005637A4 (fr) | 2019-07-29 | 2023-07-19 | Takeda Pharmaceutical Company Limited | Composé hétérocyclique |
KR102483492B1 (ko) * | 2019-09-02 | 2023-01-02 | 한양대학교 에리카산학협력단 | 2,5-이치환된 피리미딘 유도체 및 이를 포함하는 약학적 조성물 |
KR20210059632A (ko) * | 2019-11-15 | 2021-05-25 | 주식회사유한양행 | 신규의 2,3-다이하이드로-1h-인덴 또는 2,3-다이하이드로벤조퓨란 모이어티를 갖는 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법, 및 이를 포함하는 약학 조성물 |
WO2021096241A1 (fr) * | 2019-11-15 | 2021-05-20 | Yuhan Corporation | Nouveaux composés ayant une activité inhibitrice contre la glucosylcéramide synthase ou sel pharmaceutiquement acceptable de ceux-ci, leurs procédés de préparation, et compositions pharmaceutiques les comprenant |
TW202142236A (zh) * | 2020-02-03 | 2021-11-16 | 美商健臻公司 | 用於治療與溶體儲積症相關的神經症狀之方法 |
WO2021212032A1 (fr) | 2020-04-17 | 2021-10-21 | Essa Pharma, Inc. | Formes solides d'un inhibiteur de récepteur des androgènes de domaine n-terminal et leurs utilisations |
TW202220648A (zh) | 2020-07-24 | 2022-06-01 | 美商健臻公司 | 包含芬谷司他(venglustat)之醫藥組合物 |
BR112023022015A2 (pt) * | 2021-05-11 | 2023-12-26 | Green Cross Corp | Novos compostos que têm atividade inibidora contra glucosilceramida sintase ou sal farmaceuticamente aceitável da mesma, processos para preparar os mesmos e respectivas composições farmacêuticas |
WO2023101895A1 (fr) * | 2021-11-30 | 2023-06-08 | Merck Sharp & Dohme Llc | Utilisation d'analogues de pyrazole urée fusionnés en tant qu'inhibiteurs de la glucosylcéramide synthase |
WO2023172475A2 (fr) * | 2022-03-11 | 2023-09-14 | Merck Sharp & Dohme Llc | Analogues de pyrimidine cycliques non aromatiques utilisés en tant qu'inhibiteurs de glucosylcéramide synthase |
WO2023177563A2 (fr) * | 2022-03-14 | 2023-09-21 | Merck Sharp & Dohme Llc | Analogues de pyrazole amide fusionnés utilisés en tant qu'inhibiteurs de glucosylcéramide synthase |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE640616A (fr) | 1962-12-19 | |||
US3492397A (en) | 1967-04-07 | 1970-01-27 | Warner Lambert Pharmaceutical | Sustained release dosage in the pellet form and process thereof |
US4060598A (en) | 1967-06-28 | 1977-11-29 | Boehringer Mannheim G.M.B.H. | Tablets coated with aqueous resin dispersions |
US3538214A (en) | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
US4173626A (en) | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
US4593034A (en) * | 1984-04-06 | 1986-06-03 | A. H. Robins Company, Inc. | 2-alkoxy-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamides and thiobenzamides |
AU611976B2 (en) | 1987-12-24 | 1991-06-27 | John Wyeth & Brother Limited | Aroyl urea and carbamic acid derivatives of azabicyclo compounds |
EP0353372B1 (fr) * | 1988-08-04 | 1993-02-03 | Synthelabo | S-N-(1-azabicyclo [2.2.2.]oct-3-yl)benzamides et thiobenzamides ayant une activité antischizophrénique |
US5236838A (en) | 1988-12-23 | 1993-08-17 | Genzyme Corporation | Enzymatically active recombinant glucocerebrosidase |
US5549892A (en) | 1988-12-23 | 1996-08-27 | Genzyme Corporation | Enhanced in vivo uptake of glucocerebrosidase |
IT1228293B (it) | 1989-02-06 | 1991-06-07 | Angeli Inst Spa | Benzoderivati di composti eterociclici contenenti azoto. |
US5272071A (en) | 1989-12-22 | 1993-12-21 | Applied Research Systems Ars Holding N.V. | Method for the modification of the expression characteristics of an endogenous gene of a given cell line |
GB9106571D0 (en) | 1991-03-27 | 1991-05-15 | Erba Carlo Spa | Derivatives of substituted imidazol-2-one and process for their preparation |
US5968502A (en) | 1991-11-05 | 1999-10-19 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
WO1995021820A1 (fr) * | 1994-02-10 | 1995-08-17 | Yamanouchi Pharmaceutical Co., Ltd. | Nouveau derive du carbamate et composition correspondante |
US5468875A (en) * | 1994-12-22 | 1995-11-21 | American Home Products Corporation | 1-azabicycloheptane derivatives |
JPH08198751A (ja) * | 1995-01-19 | 1996-08-06 | Yamanouchi Pharmaceut Co Ltd | カルバメート誘導体 |
WO1997017348A1 (fr) | 1995-11-08 | 1997-05-15 | American Home Products Corporation | Derives 1-azabicycloheptane et leur utilisation pharmaceutique |
SE9600683D0 (sv) * | 1996-02-23 | 1996-02-23 | Astra Ab | Azabicyclic esters of carbamic acids useful in therapy |
JP2000515881A (ja) | 1996-07-29 | 2000-11-28 | フアーマシア・アンド・アツプジヨン・アー・ベー | アリールシクロアルカンカルボン酸エステル、その使用、薬剤組成物および調製 |
DE69835367T2 (de) | 1997-10-29 | 2007-08-02 | Genzyme Corp., Framingham | Gentherapie für gaucher-krankheit |
EP1125922A1 (fr) | 1998-11-02 | 2001-08-22 | Welfide Corporation | Composes de pyrrolidine et leur utilisation medicinale |
US6953855B2 (en) * | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
FR2791678B1 (fr) | 1999-03-30 | 2001-05-04 | Synthelabo | Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique |
MXPA02007632A (es) * | 2000-02-07 | 2004-08-23 | Abbott Gmbh & Co Kg | Derivados de 2-benzotiazolil urea y su uso como inhibidores de proteina cinasa. |
GB0010955D0 (en) * | 2000-05-05 | 2000-06-28 | Novartis Ag | Organic compounds |
TR200400420T4 (tr) | 2000-06-27 | 2004-03-22 | Laboratorios S.A.L.V.A.T., S.A. | Arilalkilaminlerden türetilmiş karbamatlar. |
AU2001284645A1 (en) * | 2000-08-18 | 2002-03-04 | Pharmacia And Upjohn Company | Quinuclidine-substituted aryl compounds for treatment of disease |
AU2001284646A1 (en) * | 2000-08-21 | 2002-03-04 | Pharmacia And Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
EP1231212B1 (fr) | 2001-02-06 | 2006-12-20 | Pfizer Products Inc. | Composition pharmaceutique utiles pour le traitement de troubles du SNC ou d'autres troubles |
JP2003267977A (ja) | 2002-03-14 | 2003-09-25 | Yamanouchi Pharmaceut Co Ltd | キヌクリジン誘導体 |
DE10211415A1 (de) * | 2002-03-15 | 2003-09-25 | Bayer Ag | Bicyclische N-Biarylamide |
ES2203327B1 (es) | 2002-06-21 | 2005-06-16 | Almirall Prodesfarma, S.A. | Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen. |
ES2393331T3 (es) | 2002-07-17 | 2012-12-20 | Actelion Pharmaceuticals Ltd. | Derivados de piperidintriol como inhibidores de la glucosiliceramida sintasa |
JPWO2004011430A1 (ja) | 2002-07-25 | 2005-11-24 | アステラス製薬株式会社 | ナトリウムチャネル阻害剤 |
SE0202430D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | New Compounds |
ATE378048T1 (de) * | 2002-12-06 | 2007-11-15 | The Feinstein Inst Medical Res | Hemmung von entzündungen unter verwendungvon alpha-7-rezeptor verbindenden cholinergen agonisten |
WO2004056744A1 (fr) * | 2002-12-23 | 2004-07-08 | Janssen Pharmaceutica N.V. | Adamantyl acetamides utilises comme inhibiteurs de la hydroxysteroide deshydrogenase |
TW200529860A (en) | 2003-12-22 | 2005-09-16 | Astrazeneca Ab | Nicotinic acetylcholine receptor ligands |
GB0400812D0 (en) | 2004-01-14 | 2004-02-18 | Celltech R&D Ltd | Novel compounds |
JP2007186422A (ja) | 2004-01-28 | 2007-07-26 | Astellas Pharma Inc | アリールスルフィド誘導体 |
AU2005258274A1 (en) | 2004-06-23 | 2006-01-05 | The Feinstein For Medical Research | Method of treating ileus by pharmacological activation of cholinergic receptors |
EP1811991B1 (fr) | 2004-11-10 | 2018-11-07 | Genzyme Corporation | Traitement du diabete de type 2 en utilisant d'inhibiteurs de la synthese des glycosphingolipides |
WO2006134318A1 (fr) | 2005-06-11 | 2006-12-21 | Vernalis R & D Limited | Dérivés de benzimidazole substitués au pyrazole pour une utilisation dans le traitement du cancer et de troubles auto-immuns |
WO2007038367A1 (fr) * | 2005-09-23 | 2007-04-05 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines et preparation et utilisations de ceux-ci |
US20090170847A1 (en) * | 2006-01-23 | 2009-07-02 | Seung Chul Lee | Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same |
BRPI0707245A2 (pt) * | 2006-01-23 | 2011-04-26 | Crystalgenomics Inc | derivados de imidazopiridina que inibem a atividade de proteìna quinase, método para a preparação destes e composição farmacêutica contendo os mesmos |
US20090318491A1 (en) * | 2006-01-27 | 2009-12-24 | Yale Univeristy | Cytisine and Acetylcholine Analogs and Methods of Treating Mood Disorders |
WO2008096870A1 (fr) * | 2007-02-09 | 2008-08-14 | Astellas Pharma Inc. | Composé à cycle à pont aza |
AU2008266960A1 (en) | 2007-06-20 | 2008-12-24 | Merck Sharp & Dohme Corp. | Diphenyl substituted alkanes |
GB2466912B (en) | 2007-11-29 | 2012-01-04 | Hospital For Sick Children | Compositions and methods for treating lysosomal disorders |
US8389517B2 (en) | 2008-07-28 | 2013-03-05 | Genzyme Corporation | Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease |
EP2154136A1 (fr) | 2008-08-08 | 2010-02-17 | CHIESI FARMACEUTICI S.p.A. | Dérivés de carbone de quinuclidine et ses compositions médicales |
WO2010091164A1 (fr) * | 2009-02-06 | 2010-08-12 | Exelixis, Inc. | Inhibiteurs de la glucosylcéramide synthase |
WO2010091104A1 (fr) * | 2009-02-06 | 2010-08-12 | Exelixis, Inc. | Inhibiteurs de la glucosylcéramide synthase |
ES2533954T3 (es) * | 2009-04-21 | 2015-04-16 | Nerviano Medical Sciences S.R.L. | Derivados de resorcinol como inhibidores de HSP90 |
AR077468A1 (es) * | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
LT3482767T (lt) | 2009-08-28 | 2022-01-10 | Icahn School Of Medicine At Mount Sinai | Didinamos dozės fermentų pakaitinė terapija, skirta rūgštinės sfingomielinazės nepakankamumui gydyti |
US20110183938A1 (en) * | 2009-12-16 | 2011-07-28 | Genentech, Inc. | 1,7-diazacarbazoles and methods of use |
BR112013023774B1 (pt) * | 2011-03-18 | 2022-01-11 | Genzyme Corporation | Inibidores de glicosilceramida sintase |
ES2552754T1 (es) | 2012-09-11 | 2015-12-02 | Hospira Australia Pty Ltd | Formulaciones de daptomicina y usos de la misma |
MA37975B2 (fr) * | 2012-09-11 | 2021-03-31 | Genzyme Corp | Inhibiteurs de synthase de glucosylcéramide |
-
2013
- 2013-09-09 MA MA37975A patent/MA37975B2/fr unknown
- 2013-09-09 JO JOP/2013/0273A patent/JOP20130273B1/ar active
- 2013-09-10 PT PT137658936T patent/PT2895484T/pt unknown
- 2013-09-10 WO PCT/US2013/058896 patent/WO2014043068A1/fr active Application Filing
- 2013-09-10 DK DK13765893.6T patent/DK2895484T3/da active
- 2013-09-10 EP EP13765893.6A patent/EP2895484B1/fr active Active
- 2013-09-10 PE PE2015000308A patent/PE20150734A1/es unknown
- 2013-09-10 LT LTEPPCT/US2013/058896T patent/LT2895484T/lt unknown
- 2013-09-10 ES ES13765893T patent/ES2911685T3/es active Active
- 2013-09-10 EP EP22154095.8A patent/EP4098654A1/fr active Pending
- 2013-09-10 EA EA201590554A patent/EA038536B1/ru not_active IP Right Cessation
- 2013-09-10 MX MX2020002867A patent/MX2020002867A/es unknown
- 2013-09-10 SG SG11201501538VA patent/SG11201501538VA/en unknown
- 2013-09-10 US US14/427,275 patent/US20150210681A1/en not_active Abandoned
- 2013-09-10 CA CA2884144A patent/CA2884144C/fr active Active
- 2013-09-10 NZ NZ706296A patent/NZ706296A/en unknown
- 2013-09-10 EA EA202091568A patent/EA202091568A1/ru unknown
- 2013-09-10 SG SG10201701966RA patent/SG10201701966RA/en unknown
- 2013-09-10 CN CN201810581322.8A patent/CN108864076B/zh active Active
- 2013-09-10 AU AU2013315715A patent/AU2013315715A1/en not_active Abandoned
- 2013-09-10 PL PL13765893.6T patent/PL2895484T3/pl unknown
- 2013-09-10 HU HUE13765893A patent/HUE058085T2/hu unknown
- 2013-09-10 RS RS20220379A patent/RS63130B1/sr unknown
- 2013-09-10 KR KR1020157009037A patent/KR102216532B1/ko active IP Right Grant
- 2013-09-10 CN CN201380058586.0A patent/CN105073745B/zh active Active
- 2013-09-10 BR BR112015005227A patent/BR112015005227A2/pt not_active Application Discontinuation
- 2013-09-10 MY MYPI2015000454A patent/MY186824A/en unknown
- 2013-09-10 JP JP2015531307A patent/JP6430943B2/ja active Active
- 2013-09-10 SI SI201331971T patent/SI2895484T1/sl unknown
- 2013-09-10 MX MX2015003043A patent/MX2015003043A/es active IP Right Grant
- 2013-09-10 CN CN202210106457.5A patent/CN114533729A/zh active Pending
- 2013-09-10 HR HRP20220310TT patent/HRP20220310T1/hr unknown
- 2013-09-11 AR ARP130103240A patent/AR092522A1/es unknown
- 2013-09-11 TW TW102132762A patent/TWI627171B/zh active
- 2013-09-11 UY UY0001035024A patent/UY35024A/es unknown
- 2013-10-09 UA UAA201503339A patent/UA118747C2/uk unknown
-
2015
- 2015-02-22 IL IL237355A patent/IL237355B/en active IP Right Grant
- 2015-02-25 DO DO2015000039A patent/DOP2015000039A/es unknown
- 2015-02-27 PH PH12015500431A patent/PH12015500431A1/en unknown
- 2015-03-02 GT GT201500051A patent/GT201500051A/es unknown
- 2015-03-04 CL CL2015000529A patent/CL2015000529A1/es unknown
- 2015-03-10 TN TNP2015000091A patent/TN2015000091A1/fr unknown
- 2015-03-19 CR CR20150150A patent/CR20150150A/es unknown
-
2016
- 2016-01-18 HK HK16100495.2A patent/HK1212681A1/zh unknown
-
2017
- 2017-04-18 US US15/490,385 patent/US11008316B2/en active Active
-
2021
- 2021-04-14 US US17/230,385 patent/US20220073508A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20181862T1 (hr) | Inhibitori dna-pk | |
HK1212681A1 (zh) | 葡糖神經酰胺合酶抑制劑 | |
ZA201307016B (en) | Glucosylceramide synthase inhibitors | |
IL245737B (en) | Glucosylceramide synthase inhibitors | |
HK1209422A1 (en) | Fbxo3 inhibitors fbxo3 | |
AU2019222801A1 (en) | Glucosylceramide synthase inhibitors | |
AU2018200675A1 (en) | Glucosylceramide synthase inhibitors | |
SG10201602021WA (en) | Glucosylceramide synthase inhibitors |